U.S. Markets open in 8 hrs 17 mins

The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works

Zacks Equity Research
Discover Financial's (DFS) arm pairs up with PXP to expand the acceptance of its digital payment service worldwide.

For Immediate Release

Chicago, IL – September 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Wells Fargo WFC, Schlumberger SLB, Biogen BIIB, American Express AXP and Illinois Tool Works ITW.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday’s Analyst Blog:

Top Research Reports for Wells Fargo, Schlumberger and Biogen

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo, Schlumberger and Biogen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Wells Fargo’s shares have underperformed the Zacks Major Banks industry over the past three months (+1.5% vs. +4.2%). Further, the company possesses a disappointing earnings surprise history, having beaten expectations in only one of the trailing four quarters.

Following the sales scandal and other issues, Wells Fargo has been slapped with new sanctions, including a cap on the assets position by the Federal Reserve. Recently, the bank has been charged with a penalty of $2.09 billion by the U.S. Department of Justice. The Zacks analyst thinks the crisis related to the revelation of illegally opening millions of accounts in 2016, auto-lending issues and impact of other malpractices will take some time to alleviate.

Recently, the company’s chief financial officer, John Shrewsberry, revealed a dismal picture for the bank’s loan book as well. However, lower tax rate, easing of regulations and expansions will likely support the bank’s growth profile.

(You can read the full research report on Wells Fargo here >>>).

Shares of Schlumberger have outperformed the Zacks Oil and Gas - Field Services industry over the past year, losing -10.1% vs. -13.8%. Schlumberger is the largest oilfield services player in the world with presence in every energy market.

The Zacks analyst thinks being the leading provider of technology for complex oilfield projects, Schlumberger is better placed than most peers to take up new offshore projects in the shallow water basins. In fact, the company is expecting more drilling activities to ramp up in the offshore resources, that will meet the growing demand for crude in the world.

Moreover, the firm has been persistently rewarding shareholders with higher dividend yield than the industry over the past 15 years. However, we are concerned about Schlumberger’s rising project startup costs since the company is starting up many new developments outside North America.

(You can read the full research report on Schlumberger here >>>).

Biogen’s shares have outperformed the Zacks Biomedical and Genetics industry year to date (+6.3% vs. -4.8%). Biogen has a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy.

The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer’s, Parkinson's and stroke, among others. Meanwhile, its newest drug Spinraza has multi-billion dollar potential. Biogen’s efforts to regularly in-license assets to build its pipeline are encouraging. It has many assets in its pipeline, which have transformative potential.

Multiple data readouts are expected this year. However, the launch of Ocrevus by Roche is beginning to have a negative impact on MS franchise sales in the United States. Also, Spinraza’s moderating trends in the United States is a concern.

(You can read the full research report on Biogen here >>>).

Other noteworthy reports we are featuring today include American Express and Illinois Tool Works.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Wells Fargo & Company (WFC) : Free Stock Analysis Report
 
American Express Company (AXP) : Free Stock Analysis Report
 
Illinois Tool Works Inc. (ITW) : Free Stock Analysis Report
 
Biogen Inc. (BIIB) : Free Stock Analysis Report
 
Schlumberger Limited (SLB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research